|
21 Apr 2022 |
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
|
|
20 Apr 2022 |
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
|
|
20 Apr 2022 |
Sanyou Bio congratulates Dragon Boat Pharmaceutical on the approval of clinical trials of anti-CLDN18.2 antibody drug BC008
|
|
20 Apr 2022 |
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
|
|
19 Apr 2022 |
Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
|
|
19 Apr 2022 |
Amgen announces positive top-line results from phase 3 study of ABP 654, biosimilar candidate to Stelara (ustekinumab)
|
|
15 Apr 2022 |
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
|
|
15 Apr 2022 |
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
|
|
14 Apr 2022 |
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
|
|
14 Apr 2022 |
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
|
|
14 Apr 2022 |
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
|
|
14 Apr 2022 |
CDR-Life Announces $76 Million Raised in Series A Funding
|
|
13 Apr 2022 |
Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022
|
|
13 Apr 2022 |
Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer
|
|
13 Apr 2022 |
MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product
|
|
13 Apr 2022 |
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
|
|
13 Apr 2022 |
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
|
|
11 Apr 2022 |
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
|
|
11 Apr 2022 |
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
|
|
11 Apr 2022 |
Adcendo presents Data on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
|
|
11 Apr 2022 |
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
|
|
11 Apr 2022 |
Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
|
|
11 Apr 2022 |
Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program
|
|
11 Apr 2022 |
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
|
|
11 Apr 2022 |
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
|
